P-262: Estimation of Post-Infusion Costs of Care for Patients in the US with Relapsed and Refractory Multiple Myeloma (RRMM) Who Received Idecabtagene Vicleucel (Ide-Cel, Bb2121) in the KarMMa Clinical Trial